Gyre Therapeutics (GYRE) vs Immix Biopharma (IMMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immix Biopharma (IMMX) has outperformed Gyre Therapeutics (GYRE) over the past year, gaining 278.1% versus a loss of 3.2%. Immix Biopharma is the larger company by market cap ($786.7 million vs $746.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GYRE | IMMX |
|---|---|---|
| Share price | $7.04 | $9.49 |
| Market cap | $746.48M | $786.75M |
| 1-day change | -0.56% | -1.56% |
| YTD return | -0.28% | +81.45% |
| 1-year return | -3.16% | +278.09% |
| 5-year return | -88.27% | — |
| Forward P/E | 117.33 | — |
| EPS (TTM) | $-0.25 | $-0.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.42 | $15.10 |
| 52-week low | $5.44 | $2.31 |
| Distance from 52-week high | -25.27% | -37.15% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +165.20% | +156.06% |
| Average volume | 105.59K | 1.65M |
| Shares outstanding | 106.03M | 82.90M |
| Employees | 625 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMX has outperformed GYRE by 281.3 percentage points over the past year.
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
GYRE vs IMMX FAQ
Which is bigger, Gyre Therapeutics or Immix Biopharma?
Immix Biopharma (IMMX) is larger, with a market capitalization of $786.75M compared with $746.48M for Gyre Therapeutics (GYRE).
Which stock has performed better over the past year, GYRE or IMMX?
IMMX returned +278.09% over the past 12 months, compared with -3.16% for GYRE (price return, excluding dividends). Past performance does not predict future results.
Are Gyre Therapeutics and Immix Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.